In January 2026, senior external manufacturing executives from major pharmaceutical companies and biotechs gathered in Boston to discuss the collision between political reshoring demands and manufacturing capacity constraints.

Download this report for executive insights into:

• US capacity bottlenecks in sterile fill-finish and ADCs
• The importance of China to biotech, and why tariff uncertainty has eclipsed Biosecure concerns
• Strategies for elevating External Manufacturing‘s strategic voice
• Platform approaches and selective redundancy as manufacturing strategies for the year ahead

Download this report to access our takeaways from the think tank, in partnership with Aenova.

The report is published under ‘Chatham House Rules’ with all quotes unattributed.

Complete the form to download your complimentary copy